Product image of Mirabegron Clonmel (Mirabegron) supplied by GNH India

Mirabegron Clonmel

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Clonmel (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Clonmel, is a Beta-3 adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge urinary incontinence in adult patients.

GNH India supplies Mirabegron Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Clonmel Healthcare Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mirabegron is used to manage conditions within the overactive bladder disease family by relaxing detrusor muscle tone.
  • Overactive bladder: increases bladder capacity and reduces urgency episodes.
  • Urinary urgency: lessens the sudden need to void.
  • Urinary frequency: decreases the number of daily voids.
  • Urge urinary incontinence: reduces involuntary leakage episodes.

How It Works

  • Mirabegron selectively stimulates β3‑adrenergic receptors on detrusor smooth muscle, leading to relaxation of the bladder wall during the storage phase. This pharmacologic action raises functional bladder capacity and diminishes involuntary contractions that cause urgency and incontinence, without affecting the sphincter or causing systemic adrenergic effects.

Side Effects

Common Side Effects

  • Dry mouth: mild reduction in salivation.
  • Increased blood pressure: modest rise in systolic/diastolic values.
  • Nasal congestion: sensation of a blocked nose.
  • Headache: transient cranial discomfort.
  • Constipation: reduced bowel motility.
  • Dizziness: occasional light‑headed feeling.

Serious or Rare Side Effects

  • Severe hypertension: marked elevation requiring medical attention.
  • Urinary retention: difficulty initiating or maintaining voiding.
  • Tachycardia: rapid heart rate beyond normal limits.
  • Angioedema: swelling of face, lips or throat.
  • Acute renal failure: sudden loss of kidney function.
  • Allergic reactions: rash, itching or anaphylaxis.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Cardiovascular assessment: evaluate blood pressure and heart rate.
  • Renal function: adjust use in patients with impaired kidney function.
  • Hepatic impairment: monitor liver enzymes in severe disease.
  • Concomitant antihypertensives: watch for additive blood‑pressure effects.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Avoid Interactions

Mirabegron may interact with several drug classes; monitor patients accordingly.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase Mirabegron exposure.
  • Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): risk of additive blood‑pressure reduction.

Moderate Interactions (Monitor Closely)

  • CYP3A4 substrates (e.g., midazolam, statins): possible modest increase in plasma levels.
  • Diuretics: may enhance risk of urinary retention.
  • Anticholinergics: overlapping effects on bladder function.
  • NSAIDs: potential for increased blood‑pressure changes.

Frequently Asked Questions

Mirabegron Clonmel is prescribed for adults with overactive bladder, including symptoms such as urinary urgency, increased frequency, and urge urinary incontinence. It helps relax the bladder muscle to increase capacity and reduce involuntary contractions.

Mirabegron selectively activates β3‑adrenergic receptors on the detrusor smooth muscle of the bladder. This activation causes muscle relaxation during the storage phase, which expands bladder capacity and lessens urgency and leakage episodes.

The appropriate dose of Mirabegron Clonmel is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function and other individual factors. Patients should follow the prescriber’s instructions exactly.

The safety of Mirabegron in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To request Mirabegron Clonmel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class—β3‑adrenergic agonists—whereas antimuscarinics block muscarinic receptors. Mirabegron generally has a lower incidence of dry mouth and constipation but may raise blood pressure, while antimuscarinics often cause dry mouth and blurred vision. Choice depends on patient tolerance and comorbidities.

Store Mirabegron Clonmel at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain product stability.

Mirabegron Clonmel is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include significant hypertension, urinary retention, and rare cases of angioedema or acute renal failure. Patients should be monitored for sudden increases in blood pressure, difficulty urinating, or any signs of severe allergic reaction, and seek medical attention promptly if they occur.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug. It should also be avoided in individuals with urinary retention or those taking strong CYP2D6 inhibitors without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT